Relationship between FLT3 mutation status and disease characteristics in 203 APL patients
. | Total . | WT . | ITD* . | P . | D835/I836 only . | P . |
|---|---|---|---|---|---|---|
| No. patients | 203 | 115 | 69 | 19 | ||
| Median age, y (range) | 37 (1-60) | 36 (7-60) | 41 (1-59) | .4 | 32 (4-52) | .5 |
| Median WBC count, × 109/L (range) | 3.5 (0.2-195) | 2.2 (0.3-140) | 8.9 (0.2-195) | < .001 | 8.9 (0.8-44.7) | .001 |
| Median platelet count, × 109/L (range) | 23 (3-153) | 23.5 (7-153) | 23 (3-99) | .3 | 23 (7-83) | .6 |
| Morphologic features, no. (%) | < .001 | .9 | ||||
| M3 | 63 (61) | 39 (75) | 15 (38) | 9 (69) | ||
| M3v | 37 (36) | 10 (19) | 24 (62) | 3 (23) | ||
| M3B | 4 (4) | 3 (6) | 0 (0) | 1 (8) | ||
| Unknown | 99 | 63 | 30 | 6 | ||
| Cytogenetics, no. (%) | .002 | .5 | ||||
| t(15;17) alone | 124 (66) | 60 (56) | 52 (83) | 12 (71) | ||
| t(15;17) + other abnormalities | 49 (26) | 36 (33) | 9 (14) | 4 (24) | ||
| PML-RARA+, no t(15;17) | 14 (8) | 11 (10) | 2 (3) | 1 (6) | ||
| No cytogenetics | 16 | 8 | 6 | 2 | ||
| PML breakpoint, no. (%) | < .001 | .6 | ||||
| Bcr 1/2 | 115 (65) | 77 (76) | 26 (45) | 12 (71) | ||
| Bcr 3 | 61 (35) | 24 (24) | 32 (55) | 5 (29) | ||
| Unknown | 27 | 14 | 11 | 2 | ||
| RARA-PML expression, no. (%) | .01 | > .999 | ||||
| Negative | 42 (24) | 30 (30) | 7 (12) | 5 (29) | ||
| Positive | 134 (76) | 71 (70) | 51 (85) | 12 (71) | ||
| Unknown | 27 | 14 | 11 | 2 |
. | Total . | WT . | ITD* . | P . | D835/I836 only . | P . |
|---|---|---|---|---|---|---|
| No. patients | 203 | 115 | 69 | 19 | ||
| Median age, y (range) | 37 (1-60) | 36 (7-60) | 41 (1-59) | .4 | 32 (4-52) | .5 |
| Median WBC count, × 109/L (range) | 3.5 (0.2-195) | 2.2 (0.3-140) | 8.9 (0.2-195) | < .001 | 8.9 (0.8-44.7) | .001 |
| Median platelet count, × 109/L (range) | 23 (3-153) | 23.5 (7-153) | 23 (3-99) | .3 | 23 (7-83) | .6 |
| Morphologic features, no. (%) | < .001 | .9 | ||||
| M3 | 63 (61) | 39 (75) | 15 (38) | 9 (69) | ||
| M3v | 37 (36) | 10 (19) | 24 (62) | 3 (23) | ||
| M3B | 4 (4) | 3 (6) | 0 (0) | 1 (8) | ||
| Unknown | 99 | 63 | 30 | 6 | ||
| Cytogenetics, no. (%) | .002 | .5 | ||||
| t(15;17) alone | 124 (66) | 60 (56) | 52 (83) | 12 (71) | ||
| t(15;17) + other abnormalities | 49 (26) | 36 (33) | 9 (14) | 4 (24) | ||
| PML-RARA+, no t(15;17) | 14 (8) | 11 (10) | 2 (3) | 1 (6) | ||
| No cytogenetics | 16 | 8 | 6 | 2 | ||
| PML breakpoint, no. (%) | < .001 | .6 | ||||
| Bcr 1/2 | 115 (65) | 77 (76) | 26 (45) | 12 (71) | ||
| Bcr 3 | 61 (35) | 24 (24) | 32 (55) | 5 (29) | ||
| Unknown | 27 | 14 | 11 | 2 | ||
| RARA-PML expression, no. (%) | .01 | > .999 | ||||
| Negative | 42 (24) | 30 (30) | 7 (12) | 5 (29) | ||
| Positive | 134 (76) | 71 (70) | 51 (85) | 12 (71) | ||
| Unknown | 27 | 14 | 11 | 2 |
Percentages may not add up to 100% because of rounding. P values were determined by t test for age and by Wilcoxon rank sum test for WBC and platelet counts. All comparisons are made with the WT group.
Includes 4 patients with coexistent FLT3 ITD and D835/I836.